- Home
- SVRA vs XOMA Comparison
SVRA vs XOMA Comparison
Compare SVRA & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- XOMA
- Stock Information
- Founded
- SVRA 2007
- XOMA 1981
- Country
- SVRA United States
- XOMA United States
- Employees
- SVRA N/A
- XOMA N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- XOMA Health Care
- Exchange
- SVRA Nasdaq
- XOMA Nasdaq
- Market Cap
- SVRA 527.2M
- XOMA 457.6M
- IPO Year
- SVRA N/A
- XOMA N/A
- Fundamental
- Price
- SVRA $3.95
- XOMA $33.33
- Analyst Decision
- SVRA Buy
- XOMA Strong Buy
- Analyst Count
- SVRA 8
- XOMA 2
- Target Price
- SVRA $6.88
- XOMA $69.50
- AVG Volume (30 Days)
- SVRA 1.7M
- XOMA 43.0K
- Earning Date
- SVRA 11-13-2025
- XOMA 11-05-2025
- Dividend Yield
- SVRA N/A
- XOMA N/A
- EPS Growth
- SVRA N/A
- XOMA N/A
- EPS
- SVRA N/A
- XOMA N/A
- Revenue
- SVRA N/A
- XOMA $44,952,000.00
- Revenue This Year
- SVRA N/A
- XOMA $88.91
- Revenue Next Year
- SVRA N/A
- XOMA $13.80
- P/E Ratio
- SVRA N/A
- XOMA N/A
- Revenue Growth
- SVRA N/A
- XOMA 194.98
- 52 Week Low
- SVRA $1.89
- XOMA $18.35
- 52 Week High
- SVRA $4.51
- XOMA $39.92
- Technical
- Relative Strength Index (RSI)
- SVRA 50.44
- XOMA 44.97
- Support Level
- SVRA $4.14
- XOMA $31.97
- Resistance Level
- SVRA $4.51
- XOMA $34.71
- Average True Range (ATR)
- SVRA 0.22
- XOMA 1.43
- MACD
- SVRA -0.05
- XOMA -0.09
- Stochastic Oscillator
- SVRA 11.63
- XOMA 44.06
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.